Boarding pyroptosis onto nanotechnology for cancer therapy

J Control Release. 2024 Jun:370:653-676. doi: 10.1016/j.jconrel.2024.05.014. Epub 2024 May 15.


Pyroptosis, a non-apoptotic programmed cellular inflammatory death mechanism characterized by gasdermin (GSDM) family proteins, has gathered significant attention in the cancer treatment. However, the alarming clinical trial data indicates that pyroptosis-mediated cancer therapeutic efficiency is still unsatisfactory. It is essential to integrate the burgeoning biomedical findings and innovations with potent technology to hasten the development of pyroptosis-based antitumor drugs. Considering the rapid development of pyroptosis-driven cancer nanotherapeutics, here we aim to summarize the recent advances in this field at the intersection of pyroptosis and nanotechnology. First, the foundation of pyroptosis-based nanomedicines (NMs) is outlined to illustrate the reliability and effectiveness for the treatment of tumor. Next, the emerging nanotherapeutics designed to induce pyroptosis are overviewed. Moreover, the cross-talk between pyroptosis and other cell death modalities are discussed, aiming to explore the mechanistic level relationships to provide guidance strategies for the combination of different types of antitumor drugs. Last but not least, the opportunities and challenges of employing pyroptosis-based NMs in potential clinical cancer therapy are highlighted.

Keywords: Clinical cancer therapy; Pyroptosis; Pyroptosis-based nanomedicines (NMs); Pyroptosis-driven cancer nanotherapeutics; Pyroptosis-mediated cancer therapeutic efficiency.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents* / administration & dosage
  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Nanomedicine / methods
  • Nanoparticles / administration & dosage
  • Nanotechnology / methods
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Neoplasms* / pathology
  • Neoplasms* / therapy
  • Pyroptosis* / drug effects


  • Antineoplastic Agents